keyword
MENU ▼
Read by QxMD icon Read
search

Lotus valve

keyword
https://www.readbyqxmd.com/read/29137967/procedural-and-thirty-day-outcomes-following-transfemoral-implantation-of-the-fully-repositionable-and-retrievable-lotus-valve-without-routine-pre-dilatation-in-a-consecutive-patient-cohort-a-single-centre-experience
#1
Neil Ruparelia, Katharine Thomas, James D Newton, Kate Grebenik, Amar Keiralla, George Krasopoulos, Rana Sayeed, Adrian P Banning, Rajesh K Kharbanda
BACKGROUND / PURPOSE: The Lotus valve (Boston Scientific, Natick, MA, USA) is a contemporary transcatheter aortic valve implantation (TAVI) device that is fully repositionable and retrievable to aid implantation and optimise procedural results. The ability to implant the device without routine pre-dilatation is another possible advantage reducing associated risks and procedure times. The aim of this study is to report procedural and 30-day outcomes following TAVI in a consecutive patient group presenting with severe symptomatic aortic stenosis with the Lotus valve system without routine pre-dilatation...
November 4, 2017: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://www.readbyqxmd.com/read/29130619/a-feasibility-study-of-transaxillary-tavi-with-the-lotus-valve
#2
Sagar N Doshi, Sudhakar George, Chun Shing Kwok, Anthony Mechery, Mamas Mamas, Peter F Ludman, Jonathan N Townend, Moninder Bhabra
OBJECTIVES: To assess the feasibility of axillary transcatheter aortic valve implantation (TAVI) using the Lotus valve. BACKGROUND: TAVI is used to treat patients with severe aortic stenosis, with transfemoral (TF) access being the safest and most widely used route. In patients unsuitable for this, there are reports that the axillary artery may be safest alternative access route. The Lotus device is a fully retrievable 2nd generation transcatheter heart valve which is licensed for femoral and transaortic access...
November 11, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28941127/a-comparison-of-the-fully-repositionable-and-retrievable-boston-lotus-and-direct-flow-medical-valves-for-the-treatment-of-severe-aortic-stenosis-a-single-center-experience
#3
Francesco Giannini, Azeem Latib, Matteo Montorfano, Neil Ruparelia, Vittorio Romano, Matteo Longoni, Luca Ferri, Richard Jabbour, Antonio Mangieri, Damiano Regazzoli, Marco Ancona, Nicola Buzzatti, Lorenzo Azzalini, Akihito Tanaka, Eustachio Agricola, Alaide Chieffo, Ottavio Alfieri, Antonio Colombo
BACKGROUND: Second generation transcatheter aortic valve implantation (TAVI) devices have been designed to reduce the rate of paravalvular leak (PVL) and other complications. An important technological advancement has been the ability to fully reposition devices to facilitate optimal implantation depth and position to reduce the likelihood of PVL. OBJECTIVES: To compare procedural and 30-day outcomes according to the Valve Academic Research Consortium (VARC)-2 criteria following TAVI with the fully repositionable and retrievable Lotus and DFM devices...
September 20, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28938964/predictors-of-permanent-pacemaker-implantation-after-transfemoral-aortic-valve-implantation-with-the-lotus-valve
#4
Mirjam Keßler, Birgid Gonska, Julia Seeger, Wolfgang Rottbauer, Jochen Wöhrle
BACKGROUND: Permanent pacemaker implantation (PPMI) after transcatheter aortic valve implantation is of high clinical relevance, but PPMI rates differ widely between valve types. Although the Lotus valve can be repositioned, reported rates for PPMI are high. The predictors of PPMI after Lotus valve implantation have not been defined yet. METHODS: We analyzed the impact of preexisting conduction disturbances, depth of implantation, oversizing, and amount of calcification on PPMI in 216 patients with severe symptomatic aortic stenosis underdoing Lotus valve implantation...
October 2017: American Heart Journal
https://www.readbyqxmd.com/read/28867011/tavr-with-mechanically-expandable-prostheses-is-balloon-aortic-valvuloplasty-really-necessary
#5
Giuseppe Tarantini, Luca Nai Fovino, Paola Tellaroli, Paola Purita, Giulia Masiero, Massimo Napodano, Chiara Fraccaro, Gino Gerosa, Sabino Iliceto
BACKGROUND: The fully retrievable and repositionable Lotus Valve System uses a unique mechanical expansion mechanism. Balloon aortic valvuloplasty (BAV) is recommended before valve deployment. There are no studies focusing on feasibility and efficacy of Lotus Valve implantation without previous BAV. METHODS AND RESULTS: Thirty consecutive patients (63.3% female; mean age, 80±6.2years) underwent transcatheter aortic valve replacement (TAVR) with the Lotus Valve without preparatory BAV...
November 1, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28829829/intermediate-cd14-cd16-monocytes-decline-after-transcatheter-aortic-valve-replacement-and-correlate-with-functional-capacity-and-left-ventricular-systolic-function
#6
Jonas Neuser, Paolo Galuppo, Daniela Fraccarollo, Jens Willig, Tibor Kempf, Dominik Berliner, Johann Bauersachs, Julian Daniel Widder
BACKGROUND: Transcatheter aortic valve replacement (TAVR) is the method of choice for patients with severe aortic valve stenosis, who are ineligible or at high risk for surgery. Though TAVR leads to a significant reduction in mortality, a notable amount of patients are re-hospitalized early after TAVR. Parameters or biomarkers predicting outcome are therefore needed to identify patients who benefit most. Specific monocyte subsets have been associated with cardiovascular diseases and were shown to possess prognostic value...
2017: PloS One
https://www.readbyqxmd.com/read/28818562/conduction-recovery-and-avoidance-of-permanent-pacing-after-transcatheter-aortic-valve-implantation
#7
Corinne Marzahn, Cornel Koban, Martin Seifert, Akihiro Isotani, Michael Neuß, Frank Hölschermann, Christian Butter
BACKGROUND: Transcatheter aortic valve implantation (TAVI) is an established treatment option for patients with severe aortic stenosis and high surgical risk. Currently, various prosthesis types are available. Atrioventricular block (AVB) requiring pacemaker (PM) implantation is a typical complication after TAVI. This study investigated the recovery of AV node conduction and mid-term outcome of patients with or without PM implantation after TAVI according to prosthesis type. METHODS: From July 2008 to May 2015, 856 transcatheter heart valves were implanted at our center (age: 80...
August 14, 2017: Journal of Cardiology
https://www.readbyqxmd.com/read/28797433/periprocedural-myocardial-injury-depends-on%C3%A2-transcatheter-heart-valve-type-but-does%C3%A2-not%C3%A2-predict-mortality-in-patients-after-transcatheter-aortic-valve-replacement
#8
Anja Stundl, Regina Schulte, Hannah Lucht, Marcel Weber, Alexander Sedaghat, Jasmin Shamekhi, Berndt Zur, Eberhard Grube, Fritz Mellert, Armin Welz, Rolf Fimmers, Georg Nickenig, Nikos Werner, Jan-Malte Sinning
OBJECTIVES: The aims of this study were to determine plasma elevations of biomarkers of myocardial injury associated with transfemoral (TF) transcatheter aortic valve replacement (TAVR) and to evaluate their prognostic value. BACKGROUND: Increases in biomarkers of myocardial injury are a common finding after TAVR, but their clinical significance is unclear. METHODS: In 756 consecutive TF TAVR patients, cardiac high-sensitivity troponin I (hsTnI) and creatine kinase MB (CK-MB) levels were measured at pre-defined time points to assess the occurrence of myocardial injury (defined as 15 times the upper reference limit for hsTnI [≥1...
August 14, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28760396/transcatheter-aortic-valve-replacement-with-new-generation-devices-a-systematic-review-and-meta-analysis
#9
Marco Barbanti, Sergio Buccheri, Josep Rodés-Cabau, Simona Gulino, Philippe Généreux, Gerlando Pilato, Danny Dvir, Andrea Picci, Giuliano Costa, Corrado Tamburino, Martin B Leon, John G Webb
OBJECTIVE: The aim of this study was to conduct a weighted meta-analysis to determine the rates of acute (≤30days) major outcomes after (TAVR) with second-generation devices. METHODS: A comprehensive search of multiple electronic databases from January 2011 to May 2017 was conducted using predefined criteria. New-generation TAVR devices were defined as any device which received CE mark approval or is still under evaluation for CE marking after CoreValve and SAPIEN XT prostheses...
October 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28707442/paravalvular-leak-versus-need-for-permanent-pacemaker-after-tavr-sailing-between-scylla-and-charybdis
#10
EDITORIAL
Mehmet Cilingiroglu, Konstantinos Marmagkiolis
Absence or minimization of PVL after TAVR and its potential association with higher rates of PPM placement has been the Achilles' heel of TAVR procedures. Pre-existing RBBB and depth of implantation are independent predictors of PPM need after Lotus valve implantation. Optimization of device design, increased operator experience, and focus on accurate device placement seem to result in decreased need for PPM after Lotus valve implantation.
July 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28706126/transfemoral-transcatheter-aortic-valve-in-valve-implantation-for-aortic-valve-bioprosthesis-failure-with-the-fully-repositionable-and-retrievable-lotus-valve-a-single-center-experience
#11
Neil Ruparelia, Katharine Thomas, James D Newton, Kate Grebenik, Amar Keiralla, George Krasopoulos, Rana Sayeed, Adrian P Banning, Rajesh K Kharbanda
OBJECTIVE: To report a first case series of the Lotus valve (Boston Scientific) for the treatment of surgical aortic bioprosthesis failure. BACKGROUND: Valve-in-valve (VIV) transcatheter aortic valve implantation (TAVI) is an established management option for surgical aortic bioprosthesis failure. Although TAVI has proven efficacious, complications relating to suboptimal valve implantation have been reported in approximately 5% of patients. The Lotus valve is fully repositionable and retrievable, and therefore enables complete assessment of valve function prior to definitive deployment...
July 15, 2017: Journal of Invasive Cardiology
https://www.readbyqxmd.com/read/28669697/transfemoral-lotus-valve-implantation-for-treatment-of-postendocarditis-stentless-prosthesis-degeneration-with-pure-aortic-regurgitation
#12
Marco B Ancona, Francesco Giannini, Antonio Mangieri, Damiano Regazzoli, Vittorio Romano, Manuela Giglio, Azeem Latib, Antonio Colombo, Matteo Montorfano
No abstract text is available yet for this article.
August 2017: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/28651336/safety-and-efficacy-of-a-repositionable-and-fully-retrievable-aortic-valve-used-in-routine-clinical-practice-the-respond-study
#13
Volkmar Falk, Jochen Wöhrle, David Hildick-Smith, Sabine Bleiziffer, Daniel J Blackman, Mohamed Abdel-Wahab, Ulrich Gerckens, Axel Linke, Hüseyin Ince, Peter Wenaweser, Dominic J Allocco, Keith D Dawkins, Nicolas M Van Mieghem
Aims: RESPOND is a prospective, open-label, single-arm study evaluating the outcomes following transcatheter aortic valve implantation (TAVI) with the repositionable and fully retrievable Lotus Valve used in routine clinical practice for the treatment of patients with aortic valve stenosis. Methods and results: RESPOND enrolled 1014 patients at sites across Europe, New Zealand, and Latin America; 996 patients received a Lotus Valve (mean age: 80.8 years; 50.8% female; Society of Thoracic Surgeons score: 6...
June 22, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28643214/new-generation-devices-for-transfemoral-transcatheter-aortic-valve-replacement-are-superior-compared-with-last-generation-devices-with-respect-to-varc-2-outcome
#14
Julia Seeger, Birgid Gonska, Wolfgang Rottbauer, Jochen Wöhrle
New generation devices for transcatheter aortic valve replacement have been optimized to improve clinical outcome. We compared procedural, in-hospital, 30 days and 12 months outcome of the new generation repositionable Boston Lotus Valve and the balloon-expandable Edwards Sapien 3 valve with the last generation self-expandable Medtronic CoreValve and the balloon-expandable Edwards Sapien XT. Between 2010 and 2015 consecutive patients treated with the Medtronic CoreValve (N = 100), Edwards Sapien XT (N = 100), Edwards Sapien S3 (N = 100) and Boston Lotus device (N = 100) were enrolled...
June 22, 2017: Cardiovascular Intervention and Therapeutics
https://www.readbyqxmd.com/read/28641847/lotus-valve-increasing-the-pace-of-device-iterations
#15
EDITORIAL
Philippe Généreux
No abstract text is available yet for this article.
June 26, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28641846/conduction-abnormalities-and-permanent%C3%A2-pacemaker-implantation-after-transcatheter-aortic-valve-replacement-using-the-repositionable-lotus-device-the-united-kingdom-experience
#16
Rajiv Rampat, M Zeeshan Khawaja, Roland Hilling-Smith, Jonathan Byrne, Philip MacCarthy, Daniel J Blackman, Arvindra Krishnamurthy, Ashan Gunarathne, Jan Kovac, Adrian Banning, Raj Kharbanda, Sami Firoozi, Stephen Brecker, Simon Redwood, Vinayak Bapat, Michael Mullen, Suneil Aggarwal, Ganesh Manoharan, Mark S Spence, Saib Khogali, Maureen Dooley, James Cockburn, Adam de Belder, Uday Trivedi, David Hildick-Smith
OBJECTIVES: The authors report the incidence of pacemaker implantation up to hospital discharge and the factors influencing pacing rate following implantation of the LOTUS bioprosthesis (Boston Scientific, Natick, Massachusetts) in the United Kingdom. BACKGROUND: Transcatheter aortic valve replacement (TAVR) is associated with a significant need for permanent pacemaker implantation. Pacing rates vary according to the device used. The REPRISE II (Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System) trial reported a pacing rate of 29% at 30 days after implantation of the LOTUS device...
June 26, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28622047/repositionable-and-retrievable-lotus-valve-system-for-the-treatment-of-bicuspid-aortic-stenosis-is-it-time-to-treat-all-valves
#17
Roberto Nerla, Fausto Castriota, Antonio Micari, Estevao de Campos Martins, Alberto Cremonesi
For a long time, a bicuspid valve has been considered a contraindication to transcatheter aortic valve implantation (TAVI) due to worse procedural results. Currently available technologies are changing the scenario, with initial experiences reporting much better results with second-generation devices. Areas covered: This review will analyze the risk and potential pitfalls of TAVI on bicuspid valves and will try ascertain how the use of a new-generation fully repositionable device, the Lotus Valve System (LVS), could improve procedural and clinical results in bicuspid anatomies...
June 23, 2017: Expert Review of Medical Devices
https://www.readbyqxmd.com/read/28606165/pitfalls-in-tamvi-experience-with-the-repositionable-lotus%C3%A2-valve-system
#18
Paul P Heinisch, Fabien Praz, Bernhard Winkler, Stephan Windecker, Christoph Huber, Thierry Carrel
BACKGROUND: Simultaneous transapical implantation of transcatheter heart valves in the native mitral and aortic position may be considered as an alternative to surgical valve replacement in high-risk patients presenting with combined valve disease. CASE PRESENTATION: A 59-year-old female with severe aortic stenosis, severe mitral stenosis with mild mitral insufficiency, persistent atrial fibrillation, severe chronic obstructive pulmonary disease and NYHA class of IV was evaluated by our interdisciplinary heart team...
June 12, 2017: Journal of Cardiothoracic Surgery
https://www.readbyqxmd.com/read/28566290/outcome-with-the-repositionable-and-retrievable-boston-scientific-lotus-valve-compared-with-the-balloon-expandable-edwards-sapien-3-valve-in-patients-undergoing-transfemoral-aortic-valve-replacement
#19
Julia Seeger, Birgid Gonska, Wolfgang Rottbauer, Jochen Wöhrle
BACKGROUND: New generation devices for transfemoral aortic valve replacement were optimized on valve positioning and reduction of residual aortic regurgitation. We compared 30-day, 12-month, and 24-month outcomes of the Boston Scientific Lotus valve (Lotus) and the balloon-expandable Edwards Sapien 3 (ES3) valve. Primary end point was all-cause mortality or disabling stroke within 12 months. METHODS AND RESULTS: Between 2014 and 2016, 537 patients were enrolled at our center, and 202 patients received Lotus and 335 ES3...
June 2017: Circulation. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28555592/repositionable-percutaneous-aortic-valve-implantation-with-the-lotus-valve-30-day-and-1-year-outcomes-in-250-high-risk-surgical-patients
#20
Ian T Meredith, Nicolas Dumonteil, Daniel J Blackman, Didier Tchétché, Darren L Walters, David Hildick-Smith, Ganesh Manoharan, Jan Harnek, Stephen G Worthley, Gilles Rioufol, Thierry Lefèvre, Thomas Modine, Nicolas M Van Mieghem, Ted Feldman, Dominic J Allocco, Keith D Dawkins
AIMS: The REPRISE IIE trial evaluated outcomes following transcatheter aortic valve implantation of the fully repositionable and retrievable Lotus Valve with a unique seal designed to minimize paravalvular leak (PVL). METHODS AND RESULTS: This prospective, multicentre study enrolled 250 patients with severe aortic stenosis considered high-risk for surgery by a multidisciplinary Heart Team. An independent Clinical Events Committee adjudicated events per Valve Academic Research Consortium criteria...
May 30, 2017: EuroIntervention
keyword
keyword
44527
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"